Comparative pharmacodynamics and antimutant potentials of doripenem and imipenem with ciprofloxacin-resistant Pseudomonas aeruginosa in an in vitro model

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 3, 2012, Pages 1223-1228

  Firsov, Alexander A ^a   Gilbert, Deborah ^b   Greer, Kenneth ^b   Portnoy, Yury A ^a   Zinner, Stephen H ^c  

^a GAUSE INSTITUTE OF NEW ANTIBIOTICS   (Russian Federation)

^b ROGER WILLIAMS MEDICAL CENTER   (United States)

^c MOUNT AUBURN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DORIPENEM; IMIPENEM;

ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG EFFICACY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CARBAPENEMS; CIPROFLOXACIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; HUMANS; IMIPENEM; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; MUTATION; PREDICTIVE VALUE OF TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84857166144     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05964-11     Document Type: Article

References (22)

1. Andes D, et al. 2003.PK-PD evaluation of doripenem against extended spectrum β-lactamase producing Enterobacteraceae, abstr. 182, poster 42. Posters and presentations IDSA-2003. Cognigen Corporation, Buffalo, NY.
2. Blaser J, Stone BB, Zinner SH. 1985. Two compartment kinetic model with multiple artificial capillary units. J. Antimicrob. Chemother. 15(Suppl. A):131-137. (Pubitemid 15079557)
3. Bretonnière C, et al. 2010. Efficacy of doripenem in the treatment of Pseudomonas aeruginosa experimental pneumonia versus imipenem and meropenem. J. Antimicrob. Chemother. 65:2423-2427.
4. Chamot E, El Amari EB, Rohner P, Van Delden C. 2003. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob. Agents Chemother. 47:2756-2764. (Pubitemid 37040244)
5. Chastre J, et al. 2008. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit. Care Med. 36:1089-1096. (Pubitemid 351482655)
6. Dong Y, Zhao X, Domagala J, Drlica K. 1999. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob. Agents Chemother. 43:1756-1758. (Pubitemid 29331261)
7. Firsov AA. 1993. Critical reappraisal of modern approaches to search for determinants of efficacy of antimicrobials. Eur. Bull. Drug Res. 2(Suppl. 1):33-38.
8. Firsov AA, Chernykh VM, Navashin SM. 1990. Quantitative analysis of antimicrobial effect kinetics in an in vitro dynamic model. Antimicrob. Agents Chemother. 34:1312-1317. (Pubitemid 20215765)
9. Firsov AA, Lubenko IY, Smirnova MV, Strukova EN, Zinner SH. 2008. Enrichment of fluoroquinolone-resistant Staphylococcus aureus: oscillating ciprofloxacin concentrations simulated at the upper and lower portions of the mutant selection window. Antimicrob. Agents Chemother. 52:1924-1928. (Pubitemid 351758524)
10. Firsov AA, Shevchenko AA, Vostrov SN, Zinner SH. 1998. Inter- and intra-quinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept. Antimicrob. Agents Chemother. 42:659-665. (Pubitemid 28114824)
11. Firsov AA, Vostrov SN, Shevchenko AA, Cornaglia G. 1997. Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model. Antimicrob. Agents Chemother. 41:1281-1287. (Pubitemid 27231427)
12. Firsov AA, Zinner SH. 2001. Use of modeling techniques to aid in antibiotic selection. Curr. Infect. Dis. Rep. 3:35-43.
13. Gaynes R, Edwards JR. 2005. Overview of nosocomial infections caused by gram-negative bacilli. Clin. Infect. Dis. 41:848-854. (Pubitemid 41266753)
14. Louie A, et al. 2010. Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance. Antimicrob. Agents Chemother. 54:2638 -2645.
15. Martinez JA, et al. 2010. Influence of empiric therapy with a β-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to gram-negative microorganisms. Antimicrob. Agents Chemother. 54:3590-3596.
16. McGarry LJ, et al. 2010. Economic assessment of doripenem versus imipenem in the treatment of ventilator-associated pneumonia. J. Med. Econ. 13:142-147.
17. Merchant S, et al. 2008. Hospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumonia. Clin. Ther. 30:717-733. (Pubitemid 351680488)
18. Paterson DL, DePeste DD. 2009. Doripenem. Clin. Infect. Dis. 49:291-298.
19. Peleg AY, Hooper DC. 2010. Hospital-acquired infections due to gramnegative bacteria. N. Engl. J. Med. 362:1804-1813.
20. Ray GT, Baxter R, DeLorenze GN. 2005. Hospital-level rates of fluoroquinolone use and the risk of hospital-acquired infections with ciprofloxacin-nonsusceptible Pseudomonas aeruginosa. Clin. Infect. Dis. 41:441-449. (Pubitemid 41099635)
21. Vidal F, et al. 1996. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment: analysis of 189 episodes. Arch. Intern. Med. 156:2121-2126. (Pubitemid 26346971)
22. Zhanel GG, et al. 2007. Comparative review of the carbapenems. Drugs 67:1027-1052. (Pubitemid 46744477)